Early-time-point 18F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy Cover

.blurhash-client-img { display: none !important; }

Early-time-point 18F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy

Radiology and Oncology

Volume 59 (2025): Issue 1 (March 2025)

By: Nezka Hribernik, Katja Strasek, Andrej Studen, Katarina Zevnik, Katja Skalic, Robert Jeraj and Martina Rebersek

Open Access

|Feb 2025

Additional Files

Supplementary Material 1

DOI: https://doi.org/10.2478/raon-2025-0014 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 43 - 53

Submitted on: Dec 12, 2024

|

Accepted on: Jan 4, 2025

|

Published on: Feb 27, 2025

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

early time-point ¹⁸F-FDG-PET/CT,

prognostic biomarkers,

immune-related adverse effects metastatic melanoma,

immune-checkpoint inhibitor

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2025 Nezka Hribernik, Katja Strasek, Andrej Studen, Katarina Zevnik, Katja Skalic, Robert Jeraj, Martina Rebersek, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous article Volume 59 (2025): Issue 1 (March 2025)Next article